Dow Jones Newswires: AstraZeneca’s Imfinzi plus Imjudo recommended for approval in the EU

The Anglo-Swedish pharma giant said the Committee for Medicinal Products for Human Use of the European Medicines Agency based its opinion on results from the Himalaya Phase 3 trial, and results from the Poseidon Phase 3 trial.